Abstract:
Staphylococcus aureus biofilm is responsible for two-thirds of infections resulting from surgical implants. Simvastatin is a statin drug used to reduce low-density lipoprotein cholesterol levels, but has been shown to inhibit S. aureus invasion into host cells. The use of simvastatin as an inhibitor of S. aureus biofilm was investigated, as well as the potential as an adjunct therapeutic drug when used in conjunction with oxacillin. Simvastatin was found to inhibit S. aureus biofilm growth at 0.14 mg/ml. Treatment with oxacillin (0.1 4 mg/ml) and simvastatin (0.035 mg/ml) did not enhance the ability of simvastatin to inhibit biofilm growth. However, it is important to investigate the synergistic effects between simvastatin and oxacillin.
